E2F inhibitors as anticancer agents for squamous cell carcinoma

E2F抑制剂作为鳞状细胞癌的抗癌药物

• 批准号: nhmrc : 142906
• 负责人: A/Pr Nicholas Saunders
• 金额: $ 17.14万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2001
• 资助国家: 澳大利亚
• 起止时间: 2001-01-01 至 2003-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/e2f-inhibitors-anticancer-cell-carcinoma/98265
• 关键词: E2F; inhibitors; anticancer; agents; squamous

Squamous cell carcinoma of the head and neck is one of the six most frequent causes of cancer death worldwide. these tumours are currently treated with surgery, radiotherapy and chemotherapy. Although these treatments are associated with a five year survival rate of between 40% and 60% there is a critical need for more effective and less destructive treatments. In this application we will extend on our earlier work in which we identified the protein E2F1 as being a major contributor to tumour development. In normal cells, E2F1 is required for the regulated growth of head and neck cells. However, we found that in head and neck tumours, E2F1 is overactive and contributes to the dergulated growth of the tumour. In this project we will test our newly developed inhibitors of E2F1 on various tumour cells derived from head and neck cancers to see how effective they are at stopping tumour cell growth. Furthermore we will test these compounds in animal models of head and neck cancer to determine whether they will be useful therapeutic agents for treatment of human cancer. Early results on tumour cell lines look very promising.

头颈部鳞状细胞癌是全世界癌症死亡的六个最常见原因之一。这些肿瘤目前采用手术、放疗和化疗进行治疗。尽管这些治疗方法的五年生存率在40%到60%之间，但仍然迫切需要更有效、破坏性更小的治疗方法。在本申请中，我们将扩展我们早期的工作，其中我们确定蛋白质E2F1是肿瘤发展的主要贡献者。在正常细胞中，E2F1是头颈部细胞调节生长所必需的。然而，我们发现在头颈部肿瘤中，E2F1过度活跃，导致肿瘤的无序生长。在这个项目中，我们将测试我们新开发的E2F1抑制剂对头颈癌的各种肿瘤细胞的作用，看看它们在阻止肿瘤细胞生长方面的效果如何。此外，我们将在头颈癌动物模型中测试这些化合物，以确定它们是否会成为治疗人类癌症的有用治疗剂。肿瘤细胞系的早期结果看起来非常有希望。